Heat Biologics, Inc. Announces Closing of $7,000,000 Public Offering

Jan 21, 2020

Heat Biologics, Inc. Prices $7,000,000 Public Offering

Jan 16, 2020

Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130

Dec 16, 2019

Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

Nov 20, 2019

Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

Nov 18, 2019

Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

Nov 15, 2019

Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting

Nov 11, 2019

Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment

Nov 5, 2019

Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting

Oct 24, 2019

Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update

Aug 14, 2019